To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy

A Randomized, Open-Label, Single-Dose, Three-Period Crossover Bioequivalence Study to Compare an Orodispersible Tablet (ODT) Formulation of Cetirizine HCl 10 mg Taken With and Without Water Compared With a Standard Marketed 10 mg Tablet Taken With Water

This study is designed to assess bioequivalence between two products used for treatment of allergy.

Study Overview

• Status: Completed
• Conditions: Allergy
• Intervention / Treatment: Drug: Cetirizine; Drug: Cetirizine

Detailed Description

This study is designed to evaluate if a test formulation of cetirizine 10 mg orodispersible tablet (ODT) taken with and without water is bioequivalent to a marketed reference formulation of cetirizine 10 mg tablet (Benadryl One A Day, McNeil Products Ltd, UK) taken with water. This study will also evaluate the tolerability of test and reference formulations.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Mount-Royal, Quebec, Canada, H3P 3P1
      • Algorithme Pharma Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female subjects
• Volunteers aged of at least 18 years but not older than 55 years
• Subjects will have a Body Mass Index (BMI) greater than or equal to 18.50 and below 30.00 kg/m2
• Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study
• Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance
• Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis)
• Has signed and dated the informed consent document, indicating that the subject has been informed of all pertinent aspects of the study
• Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

• Seated pulse rate below 45 bpm or higher than 90 bpm at screening
• Seated blood pressure below 90/60 mmHg or higher than 140/90 mmHg at screening
• Relationship to persons involved directly with the conduct of the study (i.e., principal investigator; sub-investigators; study coordinators; other study personnel; employees or contractors of the sponsor or Johnson & Johnson subsidiaries; and the families of each)
• Presence of any tongue piercings
• Presence of braces
• Females who are pregnant or are lactating
• Females of childbearing potential or males with a female partner of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study
• Females who are pregnant according to a positive serum pregnancy test
• Any medical history or condition, or use of any drug or medication, that the investigator determines could compromise subject safety or the evaluation of results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ODT with Water; Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water	Drug: Cetirizine; A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits; Other Names: Not yet marketed; Drug: Cetirizine; A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits; Other Names: Benadryl One A Day 10 mg Film-Coated Tablet
Experimental: ODT Without Water; Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water	Drug: Cetirizine; A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits; Other Names: Not yet marketed; Drug: Cetirizine; A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits; Other Names: Benadryl One A Day 10 mg Film-Coated Tablet
Active Comparator: FCT with Water; Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water	Drug: Cetirizine; A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits; Other Names: Not yet marketed; Drug: Cetirizine; A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits; Other Names: Benadryl One A Day 10 mg Film-Coated Tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Observed Plasma Concentration	Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered, measured in nanograms/milliliter (ng/mL)	During 32 hours post-dose
Bioavailability [AUC(0-t)]	Bioavailability [AUC(0-t)] is a measure of how much of the drug reaches the person's bloodstream within a given period of time for the body to use. The extent of product bioavailability is estimated by the area under the blood concentration vs time curve. The Area Under the Curve (AUC) is calculated by plotting the drug's blood levels on a graph at different times during the set period. The area under this curve reflects the amount of drug exposure in the set time period, calculated as hour * nanograms (ng) per milliliter (mL).	During 32 hours post-dose
Bioavailability Extrapolated to Infinity [AUC (0-∞)]	Bioavailability Extrapolated to Infinity [AUC (0-∞)] is a calculated measure of how much of the drug will ever reach the person's bloodstream for the body to use. AUC (0-∞) stands for the area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (forever). It is obtained from calculating AUC (0-t) plus AUC (t-∞).	32 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time of Maximum Concentration	The time at which maximum concentration is reached (Tmax)	During 32 hours post-dose
Terminal Elimination Rate Constant	The Terminal Elimination Rate Constant (Lamda z) is the time required to eliminate half the administered dose	During 32 hours post-dose
Terminal Phase Plasma Half-Life	Terminal phase plasma half-life (t ½) is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, rather than the time required to eliminate half the administered dose.	During 32 hours post-dose
Area under the Curve to the Tmax of the Reference Products	Area under the plasma concentration versus time curve to the time of the maximum concentration of the reference products (AUCReftmax)	During 32 hours post-dose
Relative percentage of AUCT with respect to AUC∞ (AUCT/∞)	AUCT is the area under the plasma concentration verses time curve from start of drug administration until the time of the last measurable plasma concentration. AUC∞ is the area under the plasma concentration versus time curve from start of drug administration until extrapolated infinite time. AUCT/ AUC∞ is an inversed measure of how large the extrapolated area under the curve is.	During 32 hours post-dose
Mean Residence Time	The average amount of time a particle (e.g., a drug substance molecule) remains in a compartment or system.	During 32 hours post-dose

Collaborators and Investigators

• Sponsor: McNeil AB

Study record dates

Study Major Dates

• Study Start: February 1, 2011
• Primary Completion (Actual): March 1, 2011
• Study Completion (Actual): March 1, 2011

Study Registration Dates

• First Submitted: March 23, 2011
• First Submitted That Met QC Criteria: March 23, 2011
• First Posted (Estimate): March 24, 2011

Study Record Updates

• Last Update Posted (Estimate): July 10, 2012
• Last Update Submitted That Met QC Criteria: July 6, 2012
• Last Verified: July 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Hypersensitivity; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Allergic Agents; Histamine H1 Antagonists; Histamine Antagonists; Histamine Agents; Histamine H1 Antagonists, Non-Sedating; Cetirizine
• Other Study ID Numbers: CETALY1006